A new study found that the weight loss drug Ozempic can help reduce a stroke patient’s risk of a heart attack or death. The ...

About half of all people with chronic heart failure have this type. Empagliflozin belongs to a class of medicines called SGLT2 inhibitors. Evidence demonstrates that SGLT2 inhibitors can ease the ...

The weight-loss drug Ozempic can help reduce stroke patients' risk of a heart attack or death, a new study says. GLP-1 weight ...

On the question of whether the benefits of sotagliflozin, an oral dual sodium-glucose co-transporter types 1 and 2 (SGLT1/SGLT2) inhibitor, outweigh the risks in this patient population, the committee ...

GLP-1 receptor agonists and SGLT2 inhibitors, two classes of medications most commonly prescribed to treat Type 2 diabetes or weight loss, may reduce the risk of heart attack, second strokes and death ...

In an analysis of more than 7,000 stroke survivors, those who were taking either a GLP1-receptor agonist or an SGLT2 ...

SGLT2 diabetes meds like Jardiance or Farxiga do the same, and also decrease risk of a follow-up stroke MONDAY, Nov. 11, 2024 ...

Stroke was the fourth leading cause of death in the US last year, accounting for 162,600 deaths, according to preliminary data.

In an analysis of more than 7,000 stroke survivors, those who were taking either a GLP1-receptor agonist or an SGLT2 inhibitor medication had a lower risk of a subsequent stroke, heart attack or death ...

Empagliflozin, or Empa, is a medication often used to help people with type 2 diabetes manage their blood sugar. Now, ...

There is also a strong rationale provided to avoid use of sliding-scale insulin and to consider the use of oral agents and ...